Solid Biosciences Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.59 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.59, a 60.73% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.10.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $26.23.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.58, a 28.55% decline from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.81, a 45.17% increase from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.38, a 37.66% decline from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.63, a 45.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.59 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.59 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $5.58 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $5.58 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $4.56 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $4.10 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $7.81 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $7.81 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $7.74 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $5.38 10-K · filed 2024-03-13 | |||
| 2022-12-31 | $8.63 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $5.92 10-K · filed 2022-03-14 | |||
| 2020-12-31 | $3.27 10-K · filed 2021-03-15 | |||
| 2019-12-31 | $17.72 10-K · filed 2020-03-12 | |||
| 2018-12-31 | $28.51 10-K · filed 2019-03-13 | |||
| 2018-09-30 | $28.84 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $24.78 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $26.23 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |